SecBot SecBot

PVCT

PROVECTUS BIOPHARMACEUTICALS, INC.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0000315545 Biotech & Drug Discovery
$0.0464 −0.00 (−5.31%)
Oct 27 4:00 PM ET · prev $0.0490
Next earnings
Nov 11
in 15 days
1 year
−35.6%
from $0.0720 · Oct 28
30 days
−18.6%
from $0.0570
52-week range
$0.0380–0.0730
−36% from high · low Feb 6
Avg volume 20D
63.2K
Oct 1 spike 425.8K
Short interest
801.2K
0.0%
Days to cover
5.8
at average volume
Insider net
+$100.0K
1 buyer · 0 sellers · 12 mo
Filing reports
3
analyzed by SecBot
SecBot read MIXED 3 reports · latest
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Provectus Biopharmaceuticals filed an 8-K furnishing its 2026 Annual Meeting of Stockholders presentation…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B Feb 9 1 insider buy $100.0K at $2.86

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $100.0K. No open-market sales.

  • Short sellersSTEADY

    Short interest 0.0% to 801.2K shares. 5.8 days to cover.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F
Top holderSharesValue
HUNTINGTON NATIONAL BANK1$0.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
PVCT Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 12, 2026
Earnings date
PVCT Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026
Earnings date
PVCT Q1 2026 Earnings Scheduled — 2026-05-13
Mar 26, 2026
Earnings date
PVCT Q4 2025 Earnings Scheduled — 2026-03-26

Insider ledger

Form 4
$100.0K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 23, 2026
Pershing Edward
CEO
EXERCISE7,599 sh
Oct 23, 2026
Pershing Edward
CEO
EXERCISE20,000 sh
Oct 10, 2026
Pershing Edward
CEO
EXERCISE60,000 sh
Oct 10, 2026
Pershing Edward
CEO
EXERCISE22,609 sh
Oct 3, 2026
Pershing Edward
CEO
EXERCISE35,000 sh
Oct 3, 2026
Pershing Edward
CEO
EXERCISE13,216 sh
Sep 18, 2026
Pershing Edward
CEO
EXERCISE35,000 sh
Sep 18, 2026
Pershing Edward
CEO
EXERCISE13,216 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
801,174
shares short
0.0%
vs prior settlement
5.8
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 Insider
Pershing Edward acquired via exercise 7,599 shares
CEO
Oct 23, 2026 Insider
Pershing Edward acquired via exercise 20,000 shares
CEO
Oct 10, 2026 Insider
Pershing Edward acquired via exercise 60,000 shares
CEO
Aug 12, 2026 Earnings calendar
PVCT Q2 2026 Earnings Scheduled — 2026-08-12
Jun 18, 2026 SEC
Provectus Biopharmaceuticals filed an 8-K furnishing its 2026 Annual Meeting of Stockholders presentation slides under…
8-K — Impact 2/10
Apr 30, 2026 SEC
Provectus Biopharmaceuticals filed DEFA14A additional definitive proxy soliciting materials on 2026-04-30. The filing…
DEFA14A — Impact 3/10
Apr 20, 2026 SEC
Provectus Biopharmaceuticals announced it will hold its 2026 Annual Meeting of Stockholders at Perkins Place, its…
8-K — Impact 3/10

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All PVCT filing & press-release reports (3)